Biontech Se

This study tested an updated RNA-based COVID-19 vaccine designed for the 2025-2026 season. It involved 774 participants aged 12 and older, including those 65+ and younger people with health conditions that raise their risk of severe COVID-19. Everyone received one shot, and resea…

This large study tested the Pfizer-BioNTech COVID-19 vaccine in over 11,800 healthy children aged 6 months to 12 years. Researchers looked at side effects and immune responses after different doses. The goal was to find the right dose that is safe and triggers strong protection. …

This study tested updated versions of the Pfizer-BioNTech COVID-19 vaccine designed to target newer Omicron variants (XBB.1.5, JN.1, and KP.2). Over 1,000 healthy people aged 12 and older received a single dose. The main goals were to check safety and measure the immune response.…

This study tested an experimental RNA-based vaccine called BNT165e to see if it can prevent malaria. 163 healthy adults who had never had malaria received either the vaccine or a placebo. Researchers measured safety, immune responses, and whether the vaccine protected against a c…

This early-stage trial tested an RNA-based vaccine called BNT166a against mpox (monkeypox) in 96 healthy volunteers. The goal was to check safety and see if the vaccine triggers an immune response. Researchers looked for side effects like pain, fever, and fatigue, and monitored s…

This large study tested the safety and effectiveness of the Pfizer-BioNTech mRNA vaccine (BNT162b2) against COVID-19 in nearly 47,000 healthy volunteers aged 12 and older. Participants received two doses of the vaccine or a placebo, and the trial also explored booster doses and p…

This Phase 2 trial tested the BNT162b2 mRNA vaccine in 960 healthy Chinese adults aged 18 to 85. Participants received two doses of either the vaccine or a placebo, 21 days apart. The main goal was to check safety and measure the immune response, specifically neutralizing antibod…

This study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check the vaccine's safety and find the best dose, while also looking for sig…

This study tested new modified RNA vaccines that target both influenza and COVID-19, given as a single shot. Over 2,600 healthy adults aged 18 and older took part, receiving either a flu vaccine, a COVID-19 vaccine, or a combination of both. The main goal was to check safety and …

This early-stage study tested an experimental RNA-based COVID-19 booster vaccine in 383 healthy adults who had already received a COVID-19 vaccine. The goal was to find a safe dose and see how well the body's immune system responded. Researchers looked at side effects and immune …

This early-stage trial tested two experimental vaccines (BNT164a1 and BNT164b1) against tuberculosis in 120 healthy adults who had never been exposed to TB or received the BCG vaccine. The main goal was to check safety and find the best dose. Participants received three doses of …

This study tested a single combined vaccine that aims to protect against both COVID-19 and influenza. About 8,800 healthy adults received either the combo shot or separate vaccines. Researchers checked for side effects and measured immune responses over six months to see if the c…

This large Phase 3 trial tested whether giving healthy people who already received the Pfizer-BioNTech COVID-19 vaccine one or more extra doses (boosters) is safe and effective. Over 16,000 participants in several countries received either the original vaccine, a version adapted …

This study tested several updated mRNA COVID-19 booster vaccines in over 1,400 healthy adults who had already received prior COVID-19 vaccines. The goal was to see if these new boosters are safe and can improve the immune response against newer Omicron variants. Participants rece…

This early-stage trial tested an experimental RNA vaccine called BNT165b1 in 60 healthy adults to see if it is safe and triggers an immune response against malaria. The vaccine uses messenger RNA to teach the body to recognize a key malaria protein. The study was completed and fo…

This first-in-human trial tested personalized RNA vaccines designed to target each patient's unique tumor mutations in triple negative breast cancer (TNBC). 42 participants received two custom-made vaccines to stimulate their immune system. The main goal was to check safety and t…

This phase 2 trial tested a combination of an experimental cancer vaccine (BNT111) and an immunotherapy drug (cemiplimab) in 184 adults with advanced melanoma that no longer responded to standard immunotherapy. Participants were randomly assigned to receive the combination or eit…

This early-phase trial tested two experimental drugs, BNT152 and BNT153, alone and together in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers…

This study looked for leftover cancer DNA in the blood of over 2,000 people who had surgery for stage II or III colorectal cancer. Participants did not receive any new treatment—they just gave blood samples over about 21 months. The goal was to find patients who might be eligible…